Efficacy and safety of an innovative short-course regimen containing clofazimine for treatment of drug-susceptible tuberculosis: a clinical trial
ABSTRACTIn preclinical studies, a new antituberculosis drug regimen markedly reduced the time required to achieve relapse-free cure. This study aimed to preliminarily evaluate the efficacy and safety of this four-month regimen, consisting of clofazimine, prothionamide, pyrazinamide and ethambutol, w...
Main Authors: | Xubin Zheng, Xuwei Gui, Lan Yao, Jun Ma, Yifan He, Hai Lou, Jin Gu, Ruoyan Ying, Liping Chen, Qin Sun, Yidian Liu, Chih-Ming Ho, Bai-Yu Lee, Daniel L. Clemens, Marcus A. Horwitz, Xianting Ding, Xiaohui Hao, Hua Yang, Wei Sha |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-12-01
|
Series: | Emerging Microbes and Infections |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2023.2187247 |
Similar Items
-
Spontaneous mutational patterns and novel mutations for bedaquiline and clofazimine resistance in Mycobacterium tuberculosis
by: Jin Shi, et al.
Published: (2023-10-01) -
Clofazimine as a Treatment for Multidrug-Resistant Tuberculosis: A Review
by: Rhea Veda Nugraha, et al.
Published: (2021-05-01) -
Bedaquiline resistance pattern in clofazimine-resistant clinical isolates of tuberculosis patients
by: Yuanyuan Shang, et al.
Published: (2023-06-01) -
Rv1453 is associated with clofazimine resistance in Mycobacterium tuberculosis
by: Lei Zhang, et al.
Published: (2023-10-01) -
Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of Refractory <i>Mycobacterium avium</i> Complex Pulmonary Disease
by: Bo-Guen Kim, et al.
Published: (2020-09-01)